Comparison of disease activity indices between PRI responders that met (n=52) or not (n=16) the BICLA endpoint
| Baseline | PRI R/BICLA R (n=52) Mean (SD) | PRI R/BICLA non-R (n=16) Mean (SD) | p Value* |
|---|---|---|---|
| PGA | 1.7 (0.4) | 1.8 (0.3) | 0.114 |
| SLEDAI | 10.0 (4.2) | 11.6 (5.1) | 0.203 |
| Global BILAG | 14.8 (7.0) | 18.7 (6.1) | 0.027 |
| Number of BILAG domains (A, B, C) | 2.6 (0.9) | 3.1 (0.8) | 0.065 |
| Number of BILAG domains (A, B) | 1.6 (0.8) | 2.1 (0.7) | 0.024 |
| Follow-up | |||
| PGA | 0.6 (0.4) | 1.1 (0.4) | <0.001 |
| SLEDAI | 3.0 (3.5) | 5.6 (3.5) | 0.003 |
| Global BILAG | 2.7 (3.3) | 11.6 (5.1) | <0.001 |
| Number of BILAG domains (A, B, C) | 1.6 (0.9) | 2.3 (1.0) | 0.019 |
| Number of BILAG domains (A, B) | 0.1 (0.4) | 1.2 (0.6) | <0.001 |
*Mann–Whitney rank-sum test.
BILAG, British Isles Lupus Assessment Group; BILCA, BILAG-based Composite Lupus Assessment; non-R, non-responders; PGA, physician's global assessment; PRI, physician-rated improvement; R, responders; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.